BPC-157: The Body Protection Compound
BPC-157: The Body Protection Compound
BPC-157 is one of the most researched regenerative peptides in the world. Originally isolated from human gastric juice, this is a 15-amino acid peptide.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Its amino acid sequence is:
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
This sequence has no homology to other known peptides, making this compound unique. It’s remarkably stable – remaining intact in human gastric juice for over 24 hours.
Since its discovery in the early 1990s, this peptide has been studied in over 540 scientific articles.
How BPC-157 Works
VEGFR2 Activation & Angiogenesis
This compound significantly promotes angiogenesis (new blood vessel formation) by:
- Upregulating VEGFR2 (vascular endothelial growth factor receptor 2) expression
- Activating the Akt-eNOS signaling pathway
- Promoting VEGFR2 internalization in endothelial cells
- Increasing nitric oxide production for vasodilation
Nitric Oxide System Modulation
BPC-157 activates both VEGF-dependent and VEGF-independent pathways to nitric oxide:
- VEGFR2-PI3K-Akt-eNOS pathway
- Src-Caveolin-1-eNOS pathway
Research shows this peptide disrupts the inhibitory Caveolin-1/eNOS complex, promoting sustained nitric oxide production and vasodilation.
Growth Factor Enhancement
Studies demonstrate this compound:
- Enhances growth hormone receptor expression in tendon fibroblasts
- Upregulates ERK1/2 signaling (cell growth and migration)
- Increases expression of growth-related genes (c-Fos, c-Jun, Egr-1)
- Activates Akt (cell survival pathway)
BPC-157 Safety Profile
Across preclinical studies, this compound demonstrates an excellent safety profile:
- Metabolized in liver with half-life <30 minutes
- Excreted in urine, detectable for up to 4 days
Regulatory Status
Important considerations:
- Not FDA-approved for human therapeutic use
- Classified as Category 2 bulk drug substance by FDA (2023)
- Banned by WADA under S0 category (non-approved substances)
- Available as “research chemicals” or “dietary supplements” (unregulated)
Administration
This peptide can be administered:
- Subcutaneously – most common for systemic effects
- Intramuscularly – near injury site
- Orally – stable in gastric acid, effective for gut-related applications
- Locally – direct application to injury site
The Bottom Line on BPC-157
This peptide represents one of the most comprehensively studied regenerative compounds available. Its ability to promote angiogenesis, enhance growth factor signaling, reduce inflammation, and accelerate healing across multiple tissue types makes it a compelling option for recovery and repair research. For enhanced results, researchers often combine it with TB-500 in a BPC-157 + TB500 stack. While human clinical data remains limited, the consistency of positive results across hundreds of preclinical studies has generated significant interest in the scientific and athletic communities.
Disclaimer: This article is for educational purposes only. NexGen Peptides products are intended for laboratory research use only. Not for human consumption. BPC-157 is not FDA-approved for any medical use.
References:
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. OJSM. 2025.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. J Mol Med. 2017.
- Chang CH, et al. The promoting effect of BPC 157 on tendon healing. J Appl Physiol. 2011.